Europe Records 1st Human Case of H9N2 Bird Flu in Italy

Health authorities in Italy have confirmed the first human case of the H9N2 avian influenza in Europe, marking a notable development that has revived public health concerns without triggering alarm.

The case involves a child diagnosed on March 25 after returning from a trip to Africa. The patient was admitted to a hospital in the Lombardy region, where they remain in isolation under medical supervision.

Officials reported that the condition is stable and has not developed into serious complications. 

No secondary infections have been detected among close contacts, reinforcing current scientific understanding that the virus does not spread easily between humans.

H9N2 belongs to the influenza A family, which includes other strains such as H1N1 swine flu. However, H9N2 is generally considered a low-risk virus that primarily affects birds, particularly in poultry farming environments.

Experts say the virus is not well adapted to infect humans and would require significant genetic mutations to enable efficient human-to-human transmission, a key factor in the emergence of pandemics.

Although hundreds of human cases have been reported globally, mainly in parts of Africa and Asia, Europe had not previously recorded a confirmed case. 

This has been partly attributed to differences in farming practices, including limited exposure to live bird markets compared with other regions.

The Italian case follows a familiar pattern, with mild respiratory symptoms and no severe health impact. A full recovery is expected.

Authorities have nevertheless implemented precautionary isolation and monitoring measures, reflecting the unpredictable nature of influenza viruses, which are known for their ability to mutate and recombine.

At present, there is no indication of a wider public health threat. The absence of secondary transmission, the patient’s stable condition and the virus’s limited transmissibility all suggest the risk remains low. 

However, experts stress the importance of continued vigilance in case of future mutations or interactions with other influenza strains.